Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B27PD
- Development stage
- Discontinued
- Lead developer
- Enzo Biochem
- Modality
- Peptides
- Administration
- Oral
01
Overview
B27PD is a small peptide drug developed as an oral therapy for autoimmune uveitis, a chronic intraocular inflammatory condition that can lead to vision loss. The peptide mimics the retinal S-antigen (arrestin), which is implicated in the autoimmune response underlying uveitis. By presenting this antigen orally, B27PD aims to induce immune tolerance and downregulate the pathological immune response against ocular antigens. Clinical studies have shown that treatment with B27PD can reduce inflammation and decrease reliance on immunosuppressive or anti-inflammatory medications in patients with chronic noninfectious uveitis. The drug has demonstrated safety and tolerability in early-phase clinical trials[1][3][5].
- Brand names
- OptiquelOptiquelT
- Other names
- Peptide B27PD
02
Targets
Autoreactive T-cell receptor specific for Retinal S-antigen/HLA-B27 epitopeHLA-BMHC II (Major histocompatibility complex class II receptor)SAG (S-antigen visual arrestin)
Beyond the preview
Go deeper on B27PD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B27PD.